This clinical trial is focused on studying a type of cancer called Hodgkin’s lymphoma, which affects the lymphatic system, a part of the immune system. The study is testing a combination of treatments to see how effective they are for patients whose disease has returned or did not respond to initial treatments. The treatments being studied include atezolizumab, a type of medication known as a monoclonal antibody, and a combination of drugs known as the BEGEV regimen. The BEGEV regimen includes the drugs bendamustine hydrochloride, gemcitabine, vinorelbine, and vinorelbine tartrate. These medications are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of the study is to find the best dose of atezolizumab when used with the BEGEV regimen and to see how well this combination works before patients undergo a procedure called autologous stem-cell transplantation. This procedure involves using a patient’s own stem cells to help restore their bone marrow after intensive treatment. The study is divided into two phases. In the first phase, researchers will determine the safest and most effective dose of atezolizumab. In the second phase, they will assess how well the treatment works in reducing the cancer before the stem-cell transplantation.

Participants in the study will receive the treatment over several cycles, with regular assessments to monitor their response to the therapy. The study aims to provide valuable information on the effectiveness and safety of this treatment combination for patients with relapsed or refractory Hodgkin’s lymphoma. The results will help guide future treatment options for this condition.